Like this statement:
"IPIX management made it clear all along that it intended to forge partnerships for late-stage development of Brilacidin so it can keep the entire franchise moving forward. That’s exactly where Alfasigma and Innovation were a perfect fit for each other.
For starters, Alfasigma is looking for its next IBD blockbuster and Brilacidin is at a good starting point for a deeper analysis. The data from the Phase 2 proof-of-concept trial, presented at the Crohn’s & Colitis Foundations IBD Innovate 2018, showed clinical remission at Day 42 as measured by Modified Mayo scoring for the majority of patients treated with Brilacidin. Further, mucosal healing was evidenced by endoscopic review. The trial wasn’t large, but the protocol didn’t cut any corners to demonstrate the potential of the drug, which must have impressed Alfasigma leadership."
Go IPIX!!!
"IPIX management made it clear all along that it intended to forge partnerships for late-stage development of Brilacidin so it can keep the entire franchise moving forward. That’s exactly where Alfasigma and Innovation were a perfect fit for each other.
For starters, Alfasigma is looking for its next IBD blockbuster and Brilacidin is at a good starting point for a deeper analysis. The data from the Phase 2 proof-of-concept trial, presented at the Crohn’s & Colitis Foundations IBD Innovate 2018, showed clinical remission at Day 42 as measured by Modified Mayo scoring for the majority of patients treated with Brilacidin. Further, mucosal healing was evidenced by endoscopic review. The trial wasn’t large, but the protocol didn’t cut any corners to demonstrate the potential of the drug, which must have impressed Alfasigma leadership."
Go IPIX!!!
4